Type 2 diabetes mellitus is associated with a marked increase in the risk of atherosclerotic diseases, including coronary heart disease, peripheral arterial disease, and cerebrovascular disease. Insulin resistance is a key factor in the pathogenesis of type 2 diabetes mellitus. Insulin resistance and its attendant metabolic abnormalities may cause much of the increased cardiovascular risk of type 2 diabetes mellitus. Among the abnormalities associated with insulin resistance are dyslipidemia, hypertension, systemic inflammation, and a prothrombotic state. This review discusses the role that each of these disorders plays in the cardiovascular risk of type 2 diabetes mellitus.
1. National Diabetes Data Group. Diabetes in America. 2nd ed.Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995
2.
2. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetes in the Framingham population. Diabetes23:105-111, 1974
3.
3. Miegs JB. Epidemiology of the insulin resistance syndrome. Curr Diab Rep3(1):73-79, 2003
4.
4. Consensus Development Conference on Insulin Resistance. November 5-6, 1997. American Diabetes Association. Diabetes Care 21:310-314, 1998
5.
5. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl15:41-46, 1985
6.
6. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24(4):683-689, 2001
7.
7. Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care19:387-389, 1996
8.
8. Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol. An insulin-resistant state. Diabetes43:411-417, 1994
9.
9. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev23(2):201-229, 2002
10.
10. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med57(4):551-560, 1974
11.
11. Lewis GF, Uffelman KD, Szeto LW, et al. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes42:833-942, 1993
12.
12. Miyashita Y, Shirai K, Itoh Y, et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract56(3):181-187, 2002
13.
13. Sivan E, Boden G. Free fatty acids, insulin resistance, and pregnancy. Cuff Diab Rep3(4):319-322, 2003
14.
14. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol81(4A):13B-17B, 1998
15.
15. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest J92(1):141-146, 1993
17. DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary artery disease: A complex metabolic web. J Cardiovasc Pharmacol20(Suppl 11):S1-16, 1992
18.
18. Reaven GM. Insulin resistance and its consequences: Non-insulin-dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Lippincott-Raven, Philadelphia, pp 509-519, 1996
19.
19. Cleland SJ, Petrie JR, Ueda S, et al. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension35(1 Pt 2):507-511, 2000
20.
20. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest94:1172-1179, 1994
21.
21. Utriainen T, Makimattila S, Virkamaki A, et al. Physical fitness and endothelial function (nitric oxide synthesis) are independent determinants of insulin-stimulated blood flow in normal subjects. J Clin Endocrinol Metab81:4258-4263, 1996
22.
22. Steinberg HO, Cressman E, Wu Y, et al. Insulin mediated nitric oxide production is impaired in insulin resistance. Diabetes46:24A-24A, 1997
23.
23. Muntzel MS, Anderson EA, Johnson AK, et al. Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens17:39-50, 1995
24.
24. Anderson EA, Hoffman RP, Balon TW, et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest87:2246-2252, 1991
25.
25. Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep5(3):247-254, 2003
26.
26. Resnick LM. Cellular calcium and magnesium metabolism in the pathology and treatment of hypertension and related metabolic disorders. Am J Med93(suppl 2A):IlS-19S, 1992
27.
27. Osei K. Insulin resistance and systemic resistance. Am J Cardiol84:33J-36J, 1999
28.
28. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol84:21J-24J, 1999
29.
29. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16:434-444, 1993
30.
30. Turner R, Holman R, Stratton I, et al. Tight blood pressure control and risk of macrovascular and microvascular cimplications in type 2 diabetes: UKPDS 38. BMJ317:703-713, 1998
31.
31. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med340(2):115-126 (review), 1999
32.
32. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest58(3):249-261, 1988
33.
33. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 41(4 Suppl S):S15-S22, 2003
34.
34. Hayden JM, Reaven PD. Cardiovascular disease in diabetes mellitus type 2: A potential role for novel cardiovascular risk factors. Curr Opin Lipidol11:519-528, 2000
35.
35. Ferrannini E, Natali A, Bell P, et al. On behalf of the European Group for the Study of Insulin Resistance (EGIR). Insulin resistance and hypersecretion in obesity. J Clin Invest100(5):1166-1173, 1997
36.
36. Bloomgarden Z. Inflammation and insulin resistance. Diabetes Care26(5):1619-1623, 2003
37.
37. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation97(20):2007-2011, 1998
38.
38. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation98(8):731-733, 1998
39.
39. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA279(18): 1477-1482, 1998
40.
40. Hamsten A, Wiman B, de Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med313:1557-1563, 1985
41.
41. Fuller JH, Keen H, Jarrett RJ, et al. Haemostatic variables associated with diabetes and its complications. Br Med J2:964-966, 1979
42.
42. Juhan-Vague I, Alessi M, Vague P. Increased plasma PAI- 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia34:457-462, 1991
43.
43. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications16(l):35-40, 2002
44.
44. Hayes MG, Sobel BE, Taatjes DJ, et al. Attenuation of migration of vascular smooth muscle cells by overexpression of plasminogen activator inhibitor type-i. J Am Coll of Cardiol39:203A-203A, 2002
45.
45. Chen Y, Billadello JJ, Schneider DJ. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-I gene. Arterioscler Thromb Vasc Biol20:2696-2701, 2000
46.
46. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am26:553-573, 1997
47.
47. Day C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med16:179-192, 1999
48.
48. Raji A, Plutzky J. Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions. Cuff Cardiol Rep4(6):514-521, 2002
49.
49. Yoshioka S, Nishino H, Shiraki T. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism42:75-80, 1993
50.
50. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol21(3):372-377, 2001
